Trial Profile
An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy +/- Vorinostat in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Neuroblastoma; Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Expanded access
- Sponsors Jubilant DraxImage
- 12 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2012 Additional lead trial investigator identified as reported by Vanderbilt-Ingram Cancer Center.